Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$11.22M$11.22M+505.7% vs Q2 2017 Net Income-$203.00K-$203.00KN/M vs Q2 2017 EPS Diluted$0.00$0.00N/M vs Q2 2017 Operating Income-$2,243,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,382,000N/M Margins · derivedOperating margin-20.0%+405.9 pt vs Q2 2017
Net margin-1.8%+542.4 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end